Compass Therapeutics
NASDAQ: CMPXCambridge, US · Incorporated in Delaware · 6 known investors
Compass Therapeutics develops antibody-based therapies targeting the tumor microenvironment to treat cancer. Its product candidates aim to support an effective anti-tumor immune response.
BiotechHealthtech
Investors · 6
Founder mafia
3 people who came through Compass Therapeutics went on to found or lead other companies.
+ 2 more
Competitors · 2
by search overlapSeeking Alpha33 shared keywordsSeeking Alpha is a financial research platform that provides stock analysis, investment tools, and market coverage across asset classes to investors. The platform aggregates research from thousands of analysts and investors, offering ratings, articles, and investment ideas.
Compass (NYSE:COMP)32 shared keywordsCompass is a real estate brokerage that uses technology to help consumers find homes. The company serves residential real estate buyers and sellers in the United States.
Companies competing with Compass Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Compass Therapeutics Q2 Earnings: $25.2M Net Loss | CMPX Stock Newsstocktitan.net · Aug 2026
Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update | The Manila Timesmanilatimes.net · Aug 2026Frequently asked questions
- What does Compass Therapeutics do?
- Compass Therapeutics develops antibody-based therapies targeting the tumor microenvironment to treat cancer. Its product candidates aim to support an effective anti-tumor immune response.
- Who are Compass Therapeutics's investors?
- Compass Therapeutics's investors include BioBrit, F-Prime Capital Partners, Foresite Capital, OrbiMed, venBio Partners, Vivo Capital.
- Where is Compass Therapeutics headquartered?
- Compass Therapeutics is headquartered in Cambridge, US.